Skip to main content
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Online First
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
CXCR2+ Granulocytic Myeloid-Derived Suppressor Cells with the Development of CCA: A Possible Target for Intervention
Read More
Cholangiocarcinoma
Phase 2 Study of Copanlisib plus Gemcitabine and Cisplatin in Advanced CCA
Read More
Cholangiocarcinoma
Hepatocyte-Derived Intrahepatic CCA Requires YAP and SOX9
Read More
Cholangiocarcinoma
Dose-Expansion Portion of Phase 1 Study of E7090 in Patients with CCA
Read More
1
2
3
4
Page 4 of 4
Results 31 - 34 of 34